Please assess the completion status of the following clinical trial:

Trial Title: Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The study will include three primary cohorts, with any of the following EBV+ diseases:~   Cohort A - DLBCL, 1) in first or subsequent relapse, not eligible for autologous transplantation following salvage therapy OR 2) relapse following autologous transplantation.~   Cohort B - HL, brentuximab vedotin (BV) treatment failure or unable to tolerate BV.~   Cohort C - PTLD, rituximab treatment failure.~2. Presence of active lymphoma or active PTLD, based on imaging performed within the previous 3 months.~3. Tumor positive for EBV encoded RNA (EBER) based on report from certified laboratory.~4. Absolute lymphocyte count (ALC) \>500/µL~5. Male or female ≥ 12 years of age~6. Weight ≥ 35 kg~7. Eastern Cooperative Oncology Group (ECOG) performance score 0-2, inclusively or Lansky score ≥ 60, as age appropriate~8. Able to understand and comply with the requirements of the study and to provide written informed consent or age appropriate assent for pediatric patients.~Exclusion Criteria:~1. Known central nervous system (CNS) lymphoma~2. Primary refractory HL or DLBCL~3. Bulky disease~4. Relapse or progression following previous autologous EBV specific T cell treatment.~5. Use of systemic corticosteroids \> 0.5 mg/kg/day prednisolone or equivalent does of alternative corticosteroid within 10 days prior to obtaining 200 mL starting material~6. Positive for HIV, hepatitis B, hepatitis C, syphilis or human T cell leukemia virus (HTLV).~7. Patient is pregnant or lactating~8. Systemic fungal, bacterial, viral or other infection that is not controlled~9. Prior allogeneic hematopoietic stem cell transplantation (allo HSCT)~10. Known history of primary immunodeficiency

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- baltaleucel-T (Type: EXPERIMENTAL): Treatment consist of up to 5 doses of 2x10E7 cells/m2 administered intravenously every 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).